Shannon Waller, APRN
Family · Oakland, NJNPI 1548802739
Payments from drug & device makers
Across 147 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$611
- AbbVie$302
- Boehringer Ingelheim$181
- AstraZeneca$173
- Merck$156
- Cardiovascular Systems Inc.$139
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,714100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 27 | $611 |
| AbbVie | 14 | $302 |
| Boehringer Ingelheim | 14 | $181 |
| AstraZeneca | 12 | $173 |
| Merck | 11 | $156 |
| Cardiovascular Systems Inc. | 2 | $139 |
| Esperion Therapeutics, Inc. | 8 | $121 |
| Kowa Pharmaceuticals America, Inc. | 9 | $117 |
| Lilly USA, LLC | 5 | $87 |
| Cvrx, Inc. | 3 | $77 |
| Amgen | 6 | $76 |
| Abiomed | 2 | $72 |
| Terumo Medical Corporation | 1 | $72 |
| Amarin Pharma, Inc. | 4 | $57 |
| GSK | 4 | $57 |
| Exact Sciences | 2 | $50 |
| Pfizer | 3 | $46 |
| Biohaven Pharmaceuticals, Inc. | 3 | $39 |
| Bayer | 2 | $38 |
| Novartis | 2 | $32 |
| Almatica Pharma LLC | 2 | $27 |
| Cardiva Medical, Inc. | 1 | $24 |
| Impulse Dynamics (USA) Inc. | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| ANI Pharmaceuticals, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$242
- QULIPTA$125
- Diamondback Peripheral$101
- Diamondback Coronary$101
How this compares
$2,714 in reported general payments places this provider in the 90th percentile of 2,692 family providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 32 | $33,732 |
| WegovySemaglutide | 21 | $28,210 |
| EliquisApixaban | 11 | $7,296 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $7,248 |
| Levothyroxine Sodium | 151 | $1,701 |
| Atorvastatin Calcium | 122 | $1,158 |
| Lisinopril | 74 | $753 |
| SynthroidLevothyroxine Sodium | 13 | $656 |
| Alprazolam | 143 | $610 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $567 |
| Amlodipine Besylate | 88 | $532 |
| Lorazepam | 59 | $524 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 20 | $508 |
| Escitalopram Oxalate | 54 | $503 |
| Metformin Hcl | 54 | $498 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $87 | $33,73232 claims |
| Novo NordiskWegovy | $611 | $28,21021 claims |
| PfizerEliquis | $46 | $7,29611 claims |
| MerckJanumet Xr | $156 | $7,24813 claims |
| AbbVieSynthroid | $302 | $65613 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $14 | $34330 claims |
| Almatica Pharma LLCSertraline Hcl | $27 | $33244 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,692 family providers in New Jersey.
Other family in Oakland
- Jennifer DemaioMorristown$412K
- Kara TrlicaCranbury$186K
- Nicole BauerParamus$161K
- Angie GarciaWest New York$161K
- China BattistaWall Township$142K
- Nancy EisenbergerVoorhees$82K
- Jennifer AbitabiloGlen Ridge$54K
- Megan FiloramoMorristown$53K
- Shawn DenningToms River$29K
- Kimberly ClementeEatontown$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.